150 related articles for article (PubMed ID: 36458436)
1. Epigenetic Rewiring Underlies SMARCA4-Dependent Maintenance of Progenitor State in Pediatric H3K27M Diffuse Midline Glioma.
Beytagh MC; Weiss WA
Cancer Discov; 2022 Dec; 12(12):2730-2732. PubMed ID: 36458436
[TBL] [Abstract][Full Text] [Related]
2. BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.
Panditharatna E; Marques JG; Wang T; Trissal MC; Liu I; Jiang L; Beck A; Groves A; Dharia NV; Li D; Hoffman SE; Kugener G; Shaw ML; Mire HM; Hack OA; Dempster JM; Lareau C; Dai L; Sigua LH; Quezada MA; Stanton AJ; Wyatt M; Kalani Z; Goodale A; Vazquez F; Piccioni F; Doench JG; Root DE; Anastas JN; Jones KL; Conway AS; Stopka S; Regan MS; Liang Y; Seo HS; Song K; Bashyal P; Jerome WP; Mathewson ND; Dhe-Paganon S; Suvà ML; Carcaboso AM; Lavarino C; Mora J; Nguyen QD; Ligon KL; Shi Y; Agnihotri S; Agar NYR; Stegmaier K; Stiles CD; Monje M; Golub TR; Qi J; Filbin MG
Cancer Discov; 2022 Dec; 12(12):2880-2905. PubMed ID: 36305736
[TBL] [Abstract][Full Text] [Related]
3. Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4.
Mo Y; Duan S; Zhang X; Hua X; Zhou H; Wei HJ; Watanabe J; McQuillan N; Su Z; Gu W; Wu CC; Vakoc CR; Hashizume R; Chang K; Zhang Z
Cancer Discov; 2022 Dec; 12(12):2906-2929. PubMed ID: 36305747
[TBL] [Abstract][Full Text] [Related]
4. SMARCA4 vulnerability in H3K27M midline glioma: A silver bullet for a lethal disease.
Chen CCL; Andrade AF; Jabado N
Mol Cell; 2023 Jan; 83(2):163-164. PubMed ID: 36669477
[TBL] [Abstract][Full Text] [Related]
5. Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.
Mota M; Sweha SR; Pun M; Natarajan SK; Ding Y; Chung C; Hawes D; Yang F; Judkins AR; Samajdar S; Cao X; Xiao L; Parolia A; Chinnaiyan AM; Venneti S
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2221175120. PubMed ID: 37094128
[TBL] [Abstract][Full Text] [Related]
6. Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia.
Rago F; Rodrigues LU; Bonney M; Sprouffske K; Kurth E; Elliott G; Ambrose J; Aspesi P; Oborski J; Chen JT; McDonald ER; Mapa FA; Ruddy DA; Kauffmann A; Abrams T; Bhang HC; Jagani Z
Mol Cancer Res; 2022 Mar; 20(3):361-372. PubMed ID: 34799403
[TBL] [Abstract][Full Text] [Related]
7. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
8. Chromatin Remodeling Factor BRG1 Regulates Stemness and Chemosensitivity of Glioma Initiating Cells.
Ganguly D; Sims M; Cai C; Fan M; Pfeffer LM
Stem Cells; 2018 Dec; 36(12):1804-1815. PubMed ID: 30171737
[TBL] [Abstract][Full Text] [Related]
9. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
10. The ATPase BRG1/SMARCA4 is a protein interaction platform that recruits BAF subunits and the transcriptional repressor REST/NRSF in neural progenitor cells.
Jayaprakash S; Drakulic S; Zhao Z; Sander B; Golas MM
Mol Cell Biochem; 2019 Nov; 461(1-2):171-182. PubMed ID: 31428904
[TBL] [Abstract][Full Text] [Related]
11. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.
Hoffman GR; Rahal R; Buxton F; Xiang K; McAllister G; Frias E; Bagdasarian L; Huber J; Lindeman A; Chen D; Romero R; Ramadan N; Phadke T; Haas K; Jaskelioff M; Wilson BG; Meyer MJ; Saenz-Vash V; Zhai H; Myer VE; Porter JA; Keen N; McLaughlin ME; Mickanin C; Roberts CW; Stegmeier F; Jagani Z
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3128-33. PubMed ID: 24520176
[TBL] [Abstract][Full Text] [Related]
12. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
13. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.
Wang X; Sansam CG; Thom CS; Metzger D; Evans JA; Nguyen PT; Roberts CW
Cancer Res; 2009 Oct; 69(20):8094-101. PubMed ID: 19789351
[TBL] [Abstract][Full Text] [Related]
14. Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits.
Raab JR; Runge JS; Spear CC; Magnuson T
Epigenetics Chromatin; 2017 Dec; 10(1):62. PubMed ID: 29273066
[TBL] [Abstract][Full Text] [Related]
15. Polycomb Repressive Complex 2 Confers BRG1 Dependency on the CIITA Locus.
Abou El Hassan M; Yu T; Song L; Bremner R
J Immunol; 2015 May; 194(10):5007-13. PubMed ID: 25862816
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a Brg1 hypomorphic allele demonstrates that genetic and biochemical activity are tightly correlated.
Chandler RL; Zhang Y; Magnuson T; Bultman SJ
Epigenetics; 2014 Feb; 9(2):249-56. PubMed ID: 24172864
[TBL] [Abstract][Full Text] [Related]
17. Brg1, the ATPase subunit of the SWI/SNF chromatin remodeling complex, is required for myeloid differentiation to granulocytes.
Vradii D; Wagner S; Doan DN; Nickerson JA; Montecino M; Lian JB; Stein JL; van Wijnen AJ; Imbalzano AN; Stein GS
J Cell Physiol; 2006 Jan; 206(1):112-8. PubMed ID: 15965950
[TBL] [Abstract][Full Text] [Related]
18. The core SWI/SNF catalytic subunit Brg1 regulates nephron progenitor cell proliferation and differentiation.
Basta JM; Singh AP; Robbins L; Stout L; Pherson M; Rauchman M
Dev Biol; 2020 Aug; 464(2):176-187. PubMed ID: 32504627
[TBL] [Abstract][Full Text] [Related]
19. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
[TBL] [Abstract][Full Text] [Related]
20. Targeting of BRM Sensitizes
Zernickel E; Sak A; Riaz A; Klein D; Groneberg M; Stuschke M
Mol Cancer Ther; 2019 Mar; 18(3):656-666. PubMed ID: 30478150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
